BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

PolyTherics Raises Further Funding to Enable Commercialisation of Technologies for Development of Better Biopharmaceuticals


9/7/2011 11:05:57 AM

London, 7 September 2011 - PolyTherics Limited (“PolyTherics”), a solution provider to biopharmaceutical companies for the improvement of protein and peptide based drugs, has raised £2.15 million of new finance. The funds will be used to apply the company’s proprietary polymer-protein conjugation technologies to an expanding range of proteins and peptides and to pursue new applications of these technologies. The financing round was led by Imperial Innovations Group plc (AIM: IVO), with participation from existing investor The Capital Fund, which is managed by YFM Equity Partners, and new investor Proven Health VCT PLC (LON: PHV).

Commenting on the funding, John Burt, Chief Executive Officer of PolyTherics, said: “Having recently taken up the reins at PolyTherics, I am delighted to have successfully completed this fundraising to provide a platform for the Company’s further growth. Applying our linker chemistry to novel biomolecules at an early stage can improve their properties so development can proceed with greater confidence that their biological properties will translate into therapeutic benefit.”

PolyTherics has successfully applied its PEGylation technology for half-life extension to a range of proteins and peptides, including interferons, blood factors and a variety of antibody formats, including antibody fragments (Fabs), single chain antibodies (scFv), as well as novel protein scaffolds. Avoiding the need to reengineer the protein sequence and achieving site-specific conjugation with a highly efficient process are key advantages of PolyTherics’ TheraPEG™ technology. Through collaborations, including research programmes, feasibility studies, exclusive options and licence agreements, PolyTherics is working with a growing portfolio of companies to bring forward an increasing number of new medicines. This investment follows on previous financing rounds in 2007 and 2010 which raised £5.3 million from Imperial Innovations, Longbow Capital and The Capital Fund.

PolyTherics Limited

PolyTherics is a private UK biotech company with technologies that enable the development of better biopharmaceuticals. PolyTherics has developed three proprietary technologies for attaching the polymer poly(ethylene glycol) (PEG) to any therapeutic peptide or protein in a targeted fashion. PEGylation slows elimination from the body, thereby improving half-life and potentially reducing drug treatment frequency, decreasing side effects and improving patient compliance.

PEGylated products derived from PolyTherics’ technologies are more homogeneous than those derived from traditional methods, resulting in reduced complexity of downstream processing, more consistent product quality and cost-effective manufacture. PEGylation is an established method for improving drugs and ten PEGylated products are already approved for therapeutic use worldwide.

PolyTherics commercial relationships include an option and licence agreement concluded in May 2011 with Nuron Biotech Inc. (USA) for the development of a long-acting interferon beta for the treatment of multiple sclerosis utilising PolyTherics’ TheraPEG™ technology.

For more information, please visit: www.polytherics.co.uk

For more information:

Tim Watson, Nicole Yost

College Hill

Tel: +44 (0)207 866 7861

Email: polytherics@collegehill.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES